CA3069295A1 - Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf - Google Patents

Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf Download PDF

Info

Publication number
CA3069295A1
CA3069295A1 CA3069295A CA3069295A CA3069295A1 CA 3069295 A1 CA3069295 A1 CA 3069295A1 CA 3069295 A CA3069295 A CA 3069295A CA 3069295 A CA3069295 A CA 3069295A CA 3069295 A1 CA3069295 A1 CA 3069295A1
Authority
CA
Canada
Prior art keywords
var
rvwf
vwf
infusion
von willebrand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3069295A
Other languages
English (en)
French (fr)
Inventor
Miranda CHAPMAN
Bruce EWENSTEIN
Bettina PLODER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Publication of CA3069295A1 publication Critical patent/CA3069295A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3069295A 2017-07-07 2018-07-09 Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf Pending CA3069295A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530027P 2017-07-07 2017-07-07
US62/530,027 2017-07-07
PCT/US2018/041320 WO2019010497A1 (en) 2017-07-07 2018-07-09 TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION

Publications (1)

Publication Number Publication Date
CA3069295A1 true CA3069295A1 (en) 2019-01-10

Family

ID=63036433

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3069295A Pending CA3069295A1 (en) 2017-07-07 2018-07-09 Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf

Country Status (15)

Country Link
US (5) US10632176B2 (enExample)
EP (2) EP3648788B1 (enExample)
JP (2) JP7307047B2 (enExample)
KR (1) KR20200037235A (enExample)
CN (1) CN111436193A (enExample)
AU (2) AU2018298233B2 (enExample)
BR (1) BR112020000321A2 (enExample)
CA (1) CA3069295A1 (enExample)
CO (1) CO2020001322A2 (enExample)
DK (1) DK3648788T3 (enExample)
ES (1) ES2986574T3 (enExample)
FI (1) FI3648788T5 (enExample)
PL (1) PL3648788T3 (enExample)
PT (1) PT3648788T (enExample)
WO (1) WO2019010497A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020000321A2 (pt) 2017-07-07 2020-07-14 Baxalta Incorporated método para tratamento de sangramento gastrointestinal em um sujeito com doença de von willebrand.
US20220395560A1 (en) * 2019-02-01 2022-12-15 Takeda Pharmaceutical Company Limited METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
US12128090B2 (en) * 2019-02-01 2024-10-29 Takeda Pharmaceutical Company Limited Methods of prophylactic treatment using recombinant VWF (rVWF)
WO2021032646A1 (en) * 2019-08-16 2021-02-25 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
AU591671B2 (en) 1985-04-11 1989-12-14 Children's Medical Center Corporation Von willebrand factor
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
PL1835938T3 (pl) 2004-12-27 2014-01-31 Baxalta Inc Koniugaty polimer-czynnik von Willebrandta
WO2007077217A2 (en) 2006-01-04 2007-07-12 Baxter International Inc. Oligopeptide-free cell culture media
US9107902B2 (en) 2007-06-13 2015-08-18 Csl Behring Gmbh Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
JP2011503101A (ja) 2007-11-09 2011-01-27 バクスター・インターナショナル・インコーポレイテッド 修飾された組換え第ｖｉｉｉ因子およびフォンウィルブランド因子ならびにその使用方法
JP5784907B2 (ja) 2007-12-28 2015-09-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 組換え型ｖｗｆ製剤
RU2528855C2 (ru) 2008-06-24 2014-09-20 Цсл Беринг Гмбх Модифицированный фактор виллебранда с удлиненным полупериодом существования in vivo, его применения и способы получения
AR074054A1 (es) 2008-10-21 2010-12-22 Baxter Healthcare Sa Formulaciones farmaceuticas de factor de von willebrand recombinante liofilizado
AU2010279463A1 (en) 2009-08-04 2012-03-01 Baxter Healthcare S.A. Transgenic mouse knockout for FVIII and VWF - model of hemophilia A
EP2591094B1 (en) 2010-07-08 2018-09-05 Baxalta GmbH Method of producing recombinant adamts13 in cell culture
EP3412305B1 (en) * 2011-06-10 2021-01-06 Baxalta GmbH Treatment of coagulation disease by administration of recombinant vwf
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
BR112020000321A2 (pt) 2017-07-07 2020-07-14 Baxalta Incorporated método para tratamento de sangramento gastrointestinal em um sujeito com doença de von willebrand.

Also Published As

Publication number Publication date
US20230122958A1 (en) 2023-04-20
AU2018298233B2 (en) 2025-04-24
US11529395B2 (en) 2022-12-20
BR112020000321A2 (pt) 2020-07-14
US20200206318A1 (en) 2020-07-02
US20210169989A1 (en) 2021-06-10
PT3648788T (pt) 2024-08-23
RU2020105682A3 (enExample) 2021-10-15
ES2986574T3 (es) 2024-11-12
AU2018298233A1 (en) 2020-01-30
JP2023123738A (ja) 2023-09-05
EP4424366A3 (en) 2024-12-04
JP2020526525A (ja) 2020-08-31
FI3648788T3 (fi) 2024-08-16
EP4424366A2 (en) 2024-09-04
FI3648788T5 (fi) 2024-09-09
JP7641327B2 (ja) 2025-03-06
PL3648788T3 (pl) 2024-10-07
JP7307047B2 (ja) 2023-07-11
EP3648788B1 (en) 2024-05-22
KR20200037235A (ko) 2020-04-08
AU2025205392A1 (en) 2025-09-25
RU2020105682A (ru) 2021-08-10
US10905746B2 (en) 2021-02-02
EP3648788A1 (en) 2020-05-13
US12016904B2 (en) 2024-06-25
US10632176B2 (en) 2020-04-28
CN111436193A (zh) 2020-07-21
CO2020001322A2 (es) 2020-02-18
US20240316160A1 (en) 2024-09-26
DK3648788T3 (da) 2024-08-19
US20190091299A1 (en) 2019-03-28
WO2019010497A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
US12016904B2 (en) Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
AU2025205070A1 (en) Treatment Of Patients With Severe Von Willebrand Disease Undergoing Elective Surgery By Administration Of Recombinant VWF
US12128090B2 (en) Methods of prophylactic treatment using recombinant VWF (rVWF)
US20220395560A1 (en) METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
HK40115617A (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
US20230398188A1 (en) Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
RU2774720C2 (ru) ЛЕЧЕНИЕ ЖЕЛУДОЧНО-КИШЕЧНОГО КРОВОТЕЧЕНИЯ У ПАЦИЕНТОВ С ТЯЖЕЛОЙ ФОРМОЙ БОЛЕЗНИ ФОН ВИЛЛЕБРАНДА ПУТЕМ ВВЕДЕНИЯ РЕКОМБИНАНТНОГО ФфВ
HK40029176B (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
HK40029176A (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
EA047451B1 (ru) СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
HK40029186A (en) Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
HK40029186B (en) Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20221002

EEER Examination request

Effective date: 20221002

EEER Examination request

Effective date: 20221002

EEER Examination request

Effective date: 20221002